Sep24

Just released: IMPT’s article on advancing MPTs that combine hormonal contraception and HIV prevention

Monday, 24 September 2018 Tags // action framework, contraception, HIV, hormonal, prevention

The field of MPTs that combine hormonal contraception (HC) and antiretroviral drugs for HIV prevention has made substantial progress in the past several years. There are two such MPTs in phase I clinical trials: 1) IPM’s dapivirine and levonorgestrel intravaginal ring and 2) CONRAD’s tenofovir and levonorgestrel intravaginal ring – with several other HC + ARV MPT products on the cusp in various stages of preclinical development.

Sep04

MPT field investments & collaborations are assets for global sexual health

Tuesday, 04 September 2018 Written by // Fatima Riaz, Kathryn Stewart Tags // investment, prevention, sexual health, tracking, working group

Today, on World Sexual Health Day, we at the IMPT reflect on how to work with partners to improve sexual health across the globe. There are many things that could be done, many different approaches, and many people we can work with towards this goal. Here, at the IMPT, we see multipurpose prevention technologies (MPTs) to be one such promising strategy with the potential to improve the sexual health – and lives – of women and their families across the globe.

Aug01

FROM THE PIPELINE | Taking on a challenge – How an ambitious engineering goal led to an innovative MPT for HIV, HSV, and unintended pregnancy

Wednesday, 01 August 2018 Written by // Meredith Roberts Clark, Kathleen Dietz Series // From the Pipeline Tags // challenge, clinical study, intravaginal ring, women

It all started with the simple realization that women seeking protection against HIV also want to prevent unintended pregnancies. In general, they also prefer a combined method. Then followed the innovation challenge: Engineer a long-acting intravaginal ring that could release two chemically diverse drugs – one for HIV and herpes simplex virus (HSV) prevention, and one for contraception – at sustained, controlled, and yet extremely different release rates (up to 1000-fold) for 3 months; make it suitable and scalable for use in resource-limited countries, such as those of sub-Saharan Africa; and design it so women would want to use it. Even now it’s a daunting task. When this project began, 10 years ago, its feasibility was questioned by many, including our collaborators and ourselves. However, if successful, this challenge had strong potential to provide a truly game-changing MPT solution to a dire unmet need for women globally.

<<  1 2 [34 5 6 7  >>  

Share

Spread the word about the promise of MPTs.

Collaborate

We will go further together – join the movement for MPTs.

Contribute

Your financial and in-kind support can help make MPTs a reality.